Endometrial Hyperplasia — Diagnosis and Treatment

See online here

Endometrial hyperplasia is abnormal growth of the endometrium in the uterus. It is caused by excess estrogen unopposed by progesterone. Pathology shows an increased gland-to-stroma ratio and can show atypia. Atypia is linked to endometrial cancer, the most common gynecological malignancy in the developed world. Treatment includes progesterone therapy and if there is atypic hysterectomy is recommended. Lynch syndrome has a high lifetime risk of developing endometrial cancer.

Definition and Epidemiology of Endometrial Hyperplasia

The endometrium is the innermost layer of the uterus; the other layers are the myometrium and perimetrium. Endometrial hyperplasia is an increase in the number of cells in the endometrium of the uterus. In some cases, it is associated with malignancy.

The incidence of endometrial hyperplasia is 133 women per 100,000 per year. Most cases occur in the postmenopausal years, often 50 to 54 years of age. Atypical hyperplasia is seen most commonly in 60- to 64-year-olds. Estimates of incidence are
believed to be low because many women do not report symptoms to their doctors or report after symptoms remit.

Although endometrial hyperplasia occurs mostly in postmenopausal women, it can occur at much younger ages when estrogen is unopposed, as seen in polycystic ovarian syndrome and obesity.

Some cases of endometrial hyperplasia, especially atypical, can progress to endometrial cancer, so it is important to study the two together. Endometrial cancer is the most common gynecological cancer in the developed world and the second-most common in the developing world.

Note for the United States Medical Licensing Examination (USMLE): It is important to know the list of the most common cancers in men and women. For gynecological cancers, cervical cancer is the most common in developing countries due to a lack of screening and lack of vaccination against human papillomavirus. There are 25.4 new cases per 100,000 women per year, leading to death in 4.5 per 100,000 women per year. Women have a lifetime risk of 2.8%. The average age of diagnosis is between 55 and 67 years. Only 5% of cases occur in women younger than 40 years.

Etiology of Endometrial Hyperplasia

The basic principle is that an increase in estrogen that is unopposed by progesterone leads to a proliferation of endometrial tissue.

Some important risk factors are polycystic ovarian syndrome, obesity, nulliparity, early menarche, and late menopause.

Obesity increases risk because of an excess of estrogen produced from an increased number of adipocytes. Adipocytes contain an enzyme called aromatase, which is key in the production of estrogen.

Lynch syndrome (hereditary nonpolyposis colorectal cancer) is associated with a 22%-50% lifetime risk of developing into endometrial cancer.

Note for USMLE: Lynch syndrome has an autosomal dominant inheritance. It is caused by mutations in DNA mismatch repair genes that lead to microsatellite instability. Carriers have an almost certain risk of colon cancer, and women have a high risk of gynecological cancers.

Some studies have shown that the selective estrogen receptor modulator tamoxifen increases risk due to its estrogen partial agonist effect on the endometrium.
However, a recent study from the Surveillance, Epidemiology, and end results program suggested that it does not increase overall risk.

Although rare, estradiol-secreting ovarian tumor can produce endometrial hyperplasia.

Classification of Endometrial Hyperplasia

The world health organization has two classifications for endometrial hyperplasia:

- Glandular stromal changes that are described as simple or complex
- Endometrial hyperplasia with or without atypia

This results in four categories:

- Simple without atypia
- Complex without atypia
- Simple with atypia
- Complex with atypia

Simple is described as a mild increase in gland number that may show mitosis.

Complex has an increase in gland-to-stroma ratio greater than 50% with cellular disorganization. Cells usually show mitosis.

Atypia shows nuclear enlargement with abnormal chromatin.

Endometrial carcinoma is classified into two types based upon histology, progression, incidence, and estrogen sensitivity:

- Type 1: endometrioid adenocarcinoma
- Type 2: serous/clear cell

Pathophysiology of Endometrial Hyperplasia

Endometrial hyperplasia is caused by increased amounts of estrogen unopposed by progesterone.

In a normal cycle, estrogen is released from the ovaries, which induces the endometrium to proliferate in preparation for implantation. Ovulation causes progesterone to increase, which stabilizes and prepares the endometrium for possible implantation. If no implantation occurs, then both estrogen and progesterone levels decrease and menstruation occurs.
As a woman ages and reaches **perimenopause** and **menopause**, ovulation occurs less often or not at all. Due to the lack of ovulation, there is a loss of progesterone to counteract remaining estrogen. Estrogen then allows for increased growth of the endometrium.

With increased proliferation come risks for **abnormal changes in nuclei**—atypia. **Atypia** is associated with a chance as high as 60% of having or developing **endometrial cancer**. However, in many cases, hyperplasia regresses on its own.

If **malignancy** develops, most cases are **type 1 endometrioid adenocarcinomas**, which have more favorable outcomes.

**Signs and Symptoms of Endometrial Hyperplasia**

**Abnormal uterine bleeding** is the most common reported sign.

Additional symptoms may include:

- **Menorrhagia**: increased blood loss greater than 80 mls or bleeding longer than eight days.
- **Menometrorrhagia**: increased irregular bleeding (thought of as a mix of menorrhagia and metrorrhagia)
- **Postmenopausal bleeding**

**Progression and Special Forms of Endometrial Hyperplasia**

**Atypia** has the strongest association with progression to **endometrial cancer**.

Women with **Lynch syndrome** should be screened for endometrial cancer starting at age 35 because they have a high chance of developing the disease. If a woman has undesired fertility, **hysterectomy with bilateral salpingectomy** is recommended.

**Diagnosis and Pathology of Endometrial**
Hyperplasia

No formal screening method exists for the general population, so screening usually is done when signs or symptoms are present.

The American Congress of Obstetricians and Gynecologists recommends that any woman who is older than 35 and has abnormal uterine bleeding be screened for endometrial hyperplasia. Women younger than 35 who have abnormal uterine bleeding that is not controlled with medication also should be screened.

**History and physical examination** may help to elucidate the etiology of bleeding. Physical exam may be grossly normal and show no signs of malignancy.

![Transvaginal ultrasonography procedure.](https://via.placeholder.com/150)

Initial tests can include transvaginal ultrasound to measure endometrial thickness and to screen for any other potential causes. If the endometrium is deemed to be thickened, an endometrial biopsy can be performed in the clinic. Other biopsy methods can be performed in the operating room, including dilation and curettage (commonly referred to as D and C) and hysteroscopy.

**Pathology of Endometrial Hyperplasia**

Pathology leads to a definitive diagnosis and is the best way to view changes in the endometrium. In the clinic, a pipelle is used to sample the endometrium.

**Type 1 endometrioid** is responsible for 80% of endometrial cancers, with a favorable outcome. Histology shows an increased gland-to-stroma ratio and can be referred to as adenocarcinoma because of the increased number of glands.

**Type 2 serous/clear cell** is responsible for 20% of endometrial cancers. Such cases have poorer outcomes due to myometrial and extraterine involvement. Histology depends more on the type of malignant cells seen, but most have adenocarcinoma or a mixed basis.

**Mutations** are seen in p53, PTEN, PIK3CA, K-Ras, and β-catenin.

Staging for carcinoma is done with the International Federation of Gynecology and Obstetrics (also known as FIGO) staging system or with the TNM (tumor [T], nodes [N],
and metastases (M) scale.

Differential Diagnosis of Endometrial Hyperplasia

Differentials include any cause of abnormal uterine bleeding:

- Trauma
- Neoplasm
- Atrophic vaginitis
- Polyps
- Endometritis
- Salpingitis
- Cervicitis
- Leiomyomas
- Menstruation
- Secondary bleeding due to hormone-replacement therapy

Therapy and Prevention of Endometrial Hyperplasia

Therapy depends upon the type of hyperplasia and the patient’s desire for future fertility.

Without atypia, there is a 1%-3% chance that hyperplasia will progress to endometrial cancer. **Progestin therapy** is the most accepted method for the treatment of endometrial hyperplasia without atypia.

Progestin can be given orally or released from an intramuscular injection or intrauterine device (IUD). First-line therapy includes **oral medroxyprogesterone**. Mixed estrogen-progestin oral contraceptives can be used in some patients. **Levonorgestrel IUDs**, such as the Mirena, have been shown to be very effective in treatment of endometrial hyperplasia and offer long-term contraception.

Endometrial hyperplasia without atypia has very favorable response rates, with regression occurring within three to six months. If after that time regression has not
occurred, then progestin dose should be increased.

Atypical endometrial hyperplasia has a greater risk of progressing to cancer. If future pregnancy is not desired, then **hysterectomy** is definitive treatment. In postmenopausal women, **bilateral salpingo-oophorectomy** is recommended.

If pregnancy is desired, then **progestin therapy** is used when surgery, even conservative, will not allow for pregnancy. Progestin can be given orally or released from an **intramuscular injection** or IUD. Common oral progestins are **oral megestrol acetate** and **medroxyprogesterone**.

**Intramuscular depot medroxyprogesterone (Depo-Provera) injection** four times a year has shown to be effective. Again, IUDs such as Mirena can be used as well.

If a patient continues with progestin therapy, a **biopsy** should be repeated every six to 12 months to monitor for progression.

Outcomes are generally good, with regression averaging six to nine months. Current studies show a regression rate of 86% and a relapse rate of 23%–26%.

When **metastases** possible, chemotherapy drug **cisplatin** has been shown to be effective.

**Lymph node metastasis** will go to the pelvic or para-aortic nodes. If metastasis reaches these nodes, they must be removed.

Overall, with treatment, patients endometrial cancer have a five-year survival rate of 83%.

**Complications of Endometrial Hyperplasia**

**Hysterectomy** with **bilateral salpingo-oophorectomy** in premenopausal women will lead to **surgical menopause** and result in all of the symptoms of menopause, which should be treated accordingly.

**Prevention of Endometrial Hyperplasia**

Women can take the following preventative measures:

- Women who use estrogen should take **progesterone** to prevent the unopposed estrogen effect.
- Younger women with irregular menstrual periods should be treated with **oral birth control** that contains both estrogen and progestin in order to help regulate their cycles.
- Women should maintain a **healthy body mass index**; those who are overweight or obese should lose weight.

**Cigarette smoking** has been shown to be protective against endometrial cancer. However, due to the negative effects that smoking has on the lungs and other organs, it is not recommended.

**References**

Premalignant lesions of the Endometrium via medscape.com

Endometrial Carcinoma via medscape.com
Classification and diagnosis of endometrial hyperplasia via uptodate.com

Endometrial Carcinoma: Clinical features and diagnosis via uptodate.com

SEER stat fact sheets: endometrial cancer via seer.cancer.gov

Endometrial Hyperplasia via acog.org

Endometrial Cancer via acog.org


**Legal Note:** Unless otherwise stated, all rights reserved by Lecturio GmbH. For further legal regulations see our [legal information page](#).